Ramirez-Moya et al. have confirmed that ADAR1-mediated A-to-I editing was one of the important pathways that promote thyroid cancer progression, and blocking RNA editing is a potential therapeutic target for thyroid cancer [25]. The gene discussed is ADAR; the disease is thyroid gland carcinoma.